Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

THYROGEN

(Thyrogen)

Phase 2Small molecule

GGenzyme, a Sanofi Company

THYROGEN is one of 49 small molecule programs targeting Thyroid Cancer. It is currently in Phase 2.

1

Indications

4

Total Trials

1

Active Trials

48

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Thyroid CancerRecruiting

Thyroid CancerPhase 2

Recruiting

Competition

Competitive Landscape

62 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Lenvima

Tafinlar

Keytruda

Cabometyx

Bristol-Myers Squibb

Mekinist

Retevmo

Vitrakvi

Gemzar

Johnson & Johnson

Nexavar

Gavreto

RRigel Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2035

Phase 2Recruiting

Thyroid Cancer

NCT03841617

Clinical

Trials by Indication[1]

Thyroid Cancer3 trials

A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours

Completed· Sanofi logo

Sanofi··NCT01736163·144 enrolled

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Completed· Sanofi logo

Sanofi·Phase 3·NCT00295763·61 enrolled

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03841617·30 enrolled

Withdrawal1 trial

Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00001730·20 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 30, 1998

THYROGEN

BLA BLA020898

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Thyrogen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thyrogen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thyrogen. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA020898). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Genzyme, a Sanofi Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGenzyme, a Sanofi Company

Related News